← All trials
NCT04282668
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 15, 2020
- Primary completion
- Jul 1, 2022
- Completion date
- Jul 1, 2022
- First posted
- Feb 25, 2020
- Last posted
- Feb 25, 2020
- Enrollment
- 80
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Astex Pharmaceuticals, Inc.Lead sponsor
- Astex Pharmaceuticals, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.